Women with antiphospholipid antibodies (aPL) lose pregnancies. The reason they do is unknown. Current hypotheses suggest that fetal loss is caused by placental vascular occlusion, which itself results from excess procoagulant activity (1), opposed placental anticoagulants (2), inhibited endothelial PGI2 production (3), or coagulation-independent vasculopathy (4) . Each hypothesis is based on descriptive data; none has been critically tested. The hypotheses justify therapies currently offered to women: heparin and aspirin, on the assumption that abnormal coagulation causes placental failure, or prednisone, on the assumptions that aPLs are harmful and can be suppressed (5) . These treatments have had limited success.
There are animal models for the aPL syndrome (6, 7) . Pregnant mice with aPL resorb fetuses, providing a surrogate for aPL-associated human fetal loss. But fetal resorption is not specific for aPL. CBA crossed with DBA/2 mice do not have aPL and also abort (8) . Whether the mechanisms in aPL-induced and in CBA X DBA/2 aborting mice differ at the placental level is unknown.
In this issue of TheJournal Fishman et al. abandon conventional hypotheses and introduce new ideas about aPL-induced fetal death (9) . The authors build on data derived from the CBA X DBA/2 mice: these pregnant mice have low plasma IL-3, and treatment with IL-3 prevents their abortions (8, 10). Fishman et al. demonstrate that aPL mice, too, are IL-3 deficient and respond, spectacularly, to exogenous IL-3. Since control animals have giant fetuses and early deliveries, the likely mechanism is that IL-3 induces trophoblast growth ample enough to compensate for placental ischemic atrophy. Alternatively, because thrombocytopenia and the lupus anticoagulant returned to normal in treated animals, IL-3 might have an unrecognized primary effect on coagulation. Elsewhere the same investigators showed that both aspirin and low molecular weight heparin partially prevent fetal resorptions ( 11), and clinicians believe these drugs are effective in humans. Thus data support the hypothesis that hypercoagulation is an important element ofmurine aPL-induced fetal loss but do not prove that it is a primary cause. That IL-3 corrects it suggests that hypercoagulation is not primary.
The authors are tempted to recommend IL-3 treatment trials for humans, but there are three caveats. First, it is not possible to predict which women bearing aPL will have compromised pregnancies; certainly not all do. Second, placental dysfunction in an individual patient is not quantifiable. Hence the treating physician can neither calibrate the IL-3 dose nor accurately decide when or in whom to intervene. Finally, IL-3 is far more than a trophoblast growth factor and will certainly have other effects on the mother and her child.
By suggesting a cytokine/growth factor intervention, Fishman et al. free us of the stultifying notion that coagulation abnormalities are the primary abnormality and the only reasonable target for medical intervention. Investigators and clinicians now have new worlds to explore. Michael D. Lockshin National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institutes of Health
